BioAtla Q3 net loss widens to $15.8 mln

Bioatla

13/11/2025 21:33

Overview

BioAtla Q3 net loss widens to $15.8 mln, driven by absence of collaboration revenue

R&D expenses decreased due to program prioritization and workforce reduction

Company in advanced stages to finalize strategic transaction by year-end

Outlook

BioAtla expects to complete a strategic partnership by year end

Result Drivers

Research and development (R&D) expenses were $9.5 million for the quarter ended September 30, 2025, compared to $16.4 million for the same quarter in 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$15.78 mln
Q3 Operating Expenses
$13.79 mln
Q3 Operating Income
-$13.79 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Bioatla Inc is $10.00, about 93.1% above its November 12 closing price of $0.69

Press Release: ID:nGNX4FzR5X

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)